Caló L, Cantaro S, Piccoli A, d'Angelo A, Giannini S, Williams H E, Borsatti A
Istituto di Medicina Interna, Università di Padova, Italia.
Cardiovasc Drugs Ther. 1990 Aug;4 Suppl 5:983-6. doi: 10.1007/BF02018305.
Nifedipine has been shown to lower urinary calcium in "essential" hypercalciuria. However, the mechanism(s) by which this action takes place is completely unknown. This study describes the effect of nifedipine on some calcium-controlling hormones in essential hypercalciuria. Nifedipine (20 mg/day) was administered to ten essential hypercalciuric patients, and urinary PgE2, plasma bicyclic PgE2, 1,25 vitamin D3, and PTH were assayed before and after drug administration. Nifedipine promoted a significant fall in urinary calcium (352.1 +/- 87.67 SD vs. 231.2 +/- 74.62 mg/hr; t = 7.35, p less than .0001) and PgE2 (343.92 +/- 42.71 vs. 245.03 +/- 35.41 SD ng/24 hr; t = 6.18, p less than .0002), as well as in plasma bicyclic PgE2 (310.00 +/- 30.91 vs. 200.00 +/- 31.62 SD pg/ml; t = 9.86, p less than .0001) and 1,25 (OH)2 vitamin D3 (32.77 +/- 3.23 vs. 26.94 +/- 2.94 SD pg/ml; t = 6.53, p less than .0001), while PTH remained unaltered (18.50 +/- 3.63 vs. 19.50 +/- 4.09 SD ng/ml; t = 0.85, p, ns). Urinary calcium and PgE2 correlated positively before (r = 0.81, p less than .005) but not after treatment. The fall in urinary PgE2 brought about by nifedipine seems to be due to an inhibition of PgE2 synthesis, since the absolute decrements in both urinary PgE2 and plasma PgE2 metabolites were positively correlated (r = 0.79, p less than .007). No correlation was found between the absolute decrements of plasma bicyclic PgE2 and 1,25 (OH)2 vitamin D3. These data seem to suggest that the fall in urinary calcium brought about by nifedipine is in some way related to PgE2 synthesis inhibition and to uncoupling of 1,25 (OH)2 vitamin D3 and PTH action.
硝苯地平已被证明可降低“特发性”高钙尿症患者的尿钙水平。然而,这种作用发生的机制完全未知。本研究描述了硝苯地平对特发性高钙尿症中一些钙调节激素的影响。对10例特发性高钙尿症患者给予硝苯地平(20毫克/天),并在给药前后检测尿PgE2、血浆双环PgE2、1,25-二羟维生素D3和甲状旁腺激素(PTH)。硝苯地平使尿钙(352.1±87.67标准差 vs. 231.2±74.62毫克/小时;t = 7.35,p<0.0001)、PgE2(343.92±42.71 vs. 245.03±35.41标准差纳克/24小时;t = 6.18,p<0.0002)、血浆双环PgE2(310.00±30.91 vs. 200.00±31.62标准差皮克/毫升;t = 9.86,p<0.0001)和1,25-(OH)2维生素D3(32.77±3.23 vs. 26.94±2.94标准差皮克/毫升;t = 6.53,p<0.0001)显著下降,而PTH保持不变(18.50±3.63 vs. 19.50±4.09标准差纳克/毫升;t = 0.85,p,无统计学意义)。治疗前尿钙与PgE2呈正相关(r = 0.81,p<0.005),但治疗后无相关性。硝苯地平引起的尿PgE2下降似乎是由于PgE2合成受到抑制,因为尿PgE2和血浆PgE2代谢产物的绝对减少量呈正相关(r = 0.79,p<0.007)。血浆双环PgE2和1,25-(OH)2维生素D3的绝对减少量之间未发现相关性。这些数据似乎表明,硝苯地平引起的尿钙下降在某种程度上与PgE2合成抑制以及1,25-(OH)2维生素D3和PTH作用的解偶联有关。